NASDAQ:SCLX Scilex 5/13/2024 Earnings Report $6.46 -0.03 (-0.46%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.62 +0.16 (+2.54%) As of 07/11/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Scilex EPS ResultsActual EPS-$9.10Consensus EPS -$4.20Beat/MissMissed by -$4.90One Year Ago EPSN/AScilex Revenue ResultsActual Revenue$10.88 millionExpected Revenue$15.67 millionBeat/MissMissed by -$4.79 millionYoY Revenue GrowthN/AScilex Announcement DetailsQuarterDate5/13/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsScilex's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Scilex Earnings HeadlinesSCLX Scilex Holding Company - Seeking AlphaJuly 1, 2025 | seekingalpha.comScilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...June 25, 2025 | theglobeandmail.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 12 at 2:00 AM | Porter & Company (Ad)Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the BoardJune 23, 2025 | globenewswire.comScilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review JournalJune 5, 2025 | globenewswire.comScilex Holding Stock Price HistoryJune 1, 2025 | investing.comSee More Scilex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email. Email Address About ScilexScilex (NASDAQ:SCLX), Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of non-opioid therapies for pain management. The company’s core mission is to address unmet medical needs in patients suffering from acute and chronic pain by offering innovative topical and injectable products designed to provide targeted relief while minimizing systemic exposure. Scilex’s lead marketed product is ZTlido, a lidocaine topical system approved for the treatment of peripheral neuropathic pain associated with post-herpetic neuralgia. In addition to ZTlido, the company’s clinical pipeline features novel formulations such as a dexamethasone gel intended for epidural administration following spinal surgery and exploratory programs targeting neuropathic pain and osteoarthritis. These products leverage proprietary drug-delivery technologies aimed at enhancing efficacy and convenience for patients. Formed through a strategic combination of development-stage assets in the early 2020s, Scilex is headquartered in Southern California and conducts commercial and clinical activities across the United States. The company works with a network of specialty distributors, wholesalers and direct-to-physician sales channels to ensure broad access to its therapies. Scilex also collaborates with contract research organizations and manufacturing partners to support its ongoing research and development efforts. The executive leadership team at Scilex brings together seasoned professionals with extensive backgrounds in pharmaceutical research, regulatory affairs and global commercialization. Under their guidance, the company continues to pursue strategic partnerships and licensing opportunities to expand its portfolio of non-opioid pain treatments. Looking ahead, Scilex aims to build on its existing product suite while advancing late-stage programs toward regulatory approval and market launch.Written by Jeffrey Neal JohnsonView Scilex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings America Movil (7/15/2025)Wells Fargo & Company (7/15/2025)Citigroup (7/15/2025)Charles Schwab (7/15/2025)Bank of New York Mellon (7/15/2025)Progressive (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)BlackRock (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
